top of page

Biopharma Pulse - 4/11 - 4/15 Week in Review

  • Writer: BPIQ
    BPIQ
  • Apr 15, 2022
  • 2 min read

As we have reached the middle of April, we review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and categories on BPIQ.com compared to XBI.


Table 1. BPIQ company weekly/monthly moves and YTD moves




Highlights for the week of 4/11-4/15


Biggest positive move

  • $VERU +243.7% Veru’s Novel COVID-19 Drug Candidate Reduces Deaths by 55% in Hospitalized Patients in Interim Analysis of Phase 3 Study; Independent Data Monitoring Committee Halts Study Early for Overwhelming Efficacy.


Biggest negative move

  • $BCYC -48.9% Bicycle Therapeutics Announces Interim BT8009 Phase I Clinical Trial Results at the 2022 AACR Annual Meeting.


Additional big moves

  • $RVVTF +50% Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

  • $LYRA +42.2% Lyra Therapeutics Announces Closing of $100.5 Million Private Placement.

  • $SRRA +41.3% GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn.

  • $ATNM +24.0% Actinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and North Africa.

  • MTNB +23.3% BioNTech and Matinas BioPharma Announce Exclusive Research Collaboration to Evaluate Novel Delivery Technology for mRNA-based Vaccines.

  • $INMB +12.2% INmune Bio Announces First Patient Dosed in Phase 2 XPro1595 Trial for Treatment of Neuroinflammation as a Cause of Alzheimer’s disease

  • $GALT +10.1% Galectin Therapeutics Reports the Positive Outcome of the First Data and Safety Monitoring Board for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

  • $TGTX -4.4% TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL.

  • $PRQR -12.6% ProQR Announces Additional Sepofarsen Illuminate Trial Analyses and Provides Update on Company Strategy.

  • $AGRX -13.1% AGILE THERAPEUTICS ANNOUNCES FIRST QUARTER 2022 PRESCRIPTION DATA FOR TWIRLA®

  • $NKTR -19.6% Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab)

  • $MYOV -25.1% Myovant Sciences and Pfizer Provide Update on Supplemental New Drug Application for MYFEMBREE® for the Management of Moderate to Severe Pain Associated with Endometriosis.

  • $RUBY -37.6% Rubius Therapeutics Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability

  • $FULC -37.8% Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • $ZSAN -42.7% Zosano Pharma Announces Reverse Stock Split Effective Today




Highlights for next week

  • To see next week's Big Movers HERE, subscribe. Learn more here.

  • Keep an eye out for upcoming updates on ASCO





See our Big Movers post to learn about upcoming Movers throughout April and PDUFAs, after subscribing. Learn more here.



 
 
 

Comments

bottom of page